The World Health Organization (WHO) has issued a medical product alert regarding three contaminated oral liquid medicines discovered in India, raising serious public health concerns. The contamination was reported to WHO on October 8, 2025, after clusters of acute illness and child deaths were linked to these products.
The affected medicines—COLDRIF, Respifresh TR, and ReLife—are commonly used to relieve symptoms of cold, flu, and cough. They were found to contain Diethylene Glycol (DEG), a toxic chemical harmful to humans, especially children.
What Happened?
India’s Central Drugs Standard Control Organization (CDSCO) confirmed DEG contamination in specific batches of these medicines, which are manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals, and Shape Pharma. In response, production has been halted at the implicated sites, product authorizations suspended, and a recall of the contaminated batches initiated.
Fortunately, CDSCO confirmed no evidence of these contaminated medicines being exported outside India. However, WHO urges global health authorities to conduct targeted surveillance, especially in informal or unregulated markets, to prevent any risk from similar products.
Health Risks of Contaminated Medicines
Diethylene Glycol is highly toxic and can cause severe poisoning. Symptoms include abdominal pain, vomiting, diarrhea, decreased urination, headaches, confusion, and acute kidney injury, which can be fatal if untreated.
Children are particularly vulnerable to these dangers. Using these contaminated oral liquid medicines can lead to serious injury or death.
What You Need to Know
How to Identify: Check for affected batches and products in the WHO detailed annex.
If You Have These Products: Do not use them. Contact health professionals immediately if adverse symptoms occur.
For Health Professionals: Report any adverse events related to these products to regulatory authorities and increase vigilance in monitoring the supply chain.
For Regulators and Authorities: Alert WHO promptly if these medicines are found in your market, and prioritize removing them from circulation.
Ongoing Actions
WHO is working closely with Indian authorities to investigate the contamination source and prevent further harm. Health networks worldwide should remain alert for potential risks linked to oral liquid medicines from similar manufacturers, especially products made since December 2024.
Related topics
Choosing and Using a Home BP Monitor: A Practical Guide
Massage Gun: Benefits, Techniques, and Essential Safety Guidelines
Physical Therapist: Your Partner in Restoring Movement and Improving Life
